Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs

Cotinga Pharmaceuticals (TSXV:COT) a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that the Company submitted an updated clinical package to regulatory authorities to expand its ongoing Phase 1 trial of COTI-2.

As quoted in the press release:

“Based on the strength of encouraging interim data from our ongoing Phase 1 trial, as well as preclinical studies demonstrating that COTI-2 was efficacious and synergistic when administered alongside standard of care chemotherapeutics, we are excited to push forward the development of COTI-2 as part of a combination therapy regimen,” said Alison Silva, President and Chief Executive Officer. “After close consultation with our academic collaborators and investigators, we submitted a substantially updated regulatory package to the FDA seeking approval to evaluate COTI-2 as a combination therapy in our ongoing trial. In addition to evaluating our lead asset as a combination therapy for gynecological malignancies and head and neck squamous cell carcinoma (HNSCC), the protocol amendment will also broaden the trial to include other solid tumors. We look forward to implementing this amendment and dosing the first patient with a combination therapy regimen in the months ahead.”

Click here to read the full press release.